Conditional Funding Recommendations –

Quality HTA is pleased to announce its recent paper “Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis” written by Pooyeh Grail and published online by Applied Health Economics and Health Policy is available now.

This study aimed to review the conditional reimbursement recommendations issued by CADTH and explore the reasons for those recommendations.

Out of 500 (66.6%) conditional recommendations ‘clinical criteria’ at 481 (96.2%) and ‘cost-effectiveness improvement to an acceptable level’ at 132 (26.4%) were the most frequently reported conditions. In 468 (93.6%) conditional recommendations more than one reason was reported. The most frequent reasons for conditional reimbursement were ‘clinical benefit and economic evaluation’ at 304 (60.8%), and ‘clinical benefit and economic evaluation and patient-based values’ at 91 (18.2%). Patient engagement has been added to the assessment process at CADTH  in the last decade to include patients’ value in the recommended drugs.

The clinical criteria are the cornerstone of conditional recommendations. CADTH has facilitated patient access to innovative drugs even with limited evidence by conditional recommendations.

Available here!